Hikma Pharmaceuticals and Bio-Thera Solutions enter into commercialisation and license agreement


Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Hikma Pharmaceuticals and Bio-Thera Solutions have entered into a commercialisation and license agreement to commercialise BAT2206, a monoclonal antibody that is a proposed biosimilar to Jansen’s Stelara ®, in the US.

It is currently in global phase three clinical trial.

Under the terms of the agreement, Bio-Thera will be responsible for development, manufacturing, and supply of BAT2206.

Hikma will have exclusive rights to commercialize the product in the US.

Bio-Thera is eligible for an upfront payment of $20 million and development and commercial milestones of up to $130 million.

‘This partnership provides us with a unique opportunity to enter the biosimilar market in the US, building on our position as a leading generic manufacturer in the US,’ said Siggi Olafsson, chief executive officer of Hikma.